|drug3488||Tocilizumab 180 MG/ML Wiki||0.71|
|drug2560||Placebo solution Wiki||0.71|
|drug2718||Q16 testing Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
This is a double-blind, randomized, placebo-controlled, phase IIb clinical trial to assess the efficacy of injectable methylprednisolone sodium succinate (MP) in patients with severe acute respiratory syndrome (SARS) in COVID-19 infection. A total of 416 individuals of both sexes, aged over 18 years old, with symptoms suggestive or confirmed diagnosis of severe acute respiratory syndrome (SARS), hospitalized at the Hospital and Pronto-Socorro Delphina Rinaldi Abdel Aziz (HPSDRAA), with clinical and radiological findings suggestive of SARS-CoV2 infection, will be randomized at a 1:1 ration to receive either MP (0.5mg/kg of weight, twice daily, for 5 days) or placebo (saline solution, twice daily, for 5 days).
Description: Mortality rate on day 28, after randomizationMeasure: Mortality rate at day 28 Time: on day 28, after randomization
Description: Proportion of patient that died on days 7, 14 and 28.Measure: Mortality rate on days 7, 14 and 28 Time: after randomization, up to 28 days.
Description: proportion of patients requiring orotracheal intubationMeasure: Incidence of orotracheal intubation Time: after randomization, up to 7 days.
Description: Proportion of patients with oxygenation index (PaO2 / FiO2) < 100 in 7 days.Measure: Change in oxygenation index Time: after randomization, up to 7 days.
This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19
Description: A seven-category ordinal scale consisting of: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.Measure: Patient clinical status 15 days after randomization Time: 15 days after randomization
Description: Improvement in PaO2/FIO2Measure: Improving oxygenation Time: 15 days
Description: Improvement in the computed tomography between D0 and D10 after randomizationMeasure: Thorax CT improvement Time: 10 days
Description: Duration o ICU stay in daysMeasure: ICU length of stay Time: 28 days
Description: Days of mechanical ventilationMeasure: Duration of mechanical ventilation Time: 28 days
Description: AKI according to Kidney Disease Improving Global Outcomes (KDIGO)Measure: Incidence of acute kidney (AKI) with necessity of renal replacement therapy Time: 15 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports